Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_assertion type Assertion NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_head.
- NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_assertion description "[Patients with previously untreated, recurrent, or metastatic SCCHN were treated with pemetrexed 500 mg/m(2) and bevacizumab 15 mg/kg given intravenously every 21 days with folic acid and B(12) supplementation until disease progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_provenance.
- NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_assertion evidence source_evidence_literature NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_provenance.
- NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_assertion SIO_000772 21343546 NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_provenance.
- NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_assertion wasDerivedFrom befree-20140225 NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_provenance.
- NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_assertion wasGeneratedBy ECO_0000203 NP674391.RAspZaZFhK6GFbHOjkAD2XuETOc1Pu7QTStNMRHlJDJzA130_provenance.